Schering-Plough buys China partners

Although the company is staying tight-lipped on the details of the deals, here's a mouthful: Schering-Plough announced yesterday that it purchased Shanghai Pharmaceutical Industry and Shanghai Pharmaceutical Group, and will establish Shanghai Shering-Plough Pharmaceutical as a wholly owned operation in Shanghai.

The buyout comes after a longstanding relationship with the companies, which Schering-Plough has been working with to dispense allergy and skincare products with since 1994. 

- see the Schering-Plough release
- read the story at CNN Money
- see what Business Week says
- find the PharmaLive blog post
- get the latest at Forbes

Suggested Articles

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.

After a jury ordered Gilead's Kite Pharma to pay $752 million for CAR-T patent infringement, BMS is asking for punitive damages in that amount, too.